EU/3/02/104

Table of contents

About

On 12 June 2002, orphan designation (EU/3/02/104) was granted by the European Commission to Zentaris Aktiengesellschaft, Germany, for miltefosine for the treatment of visceral leishmaniasis.

Key facts

Active substance
Miltefosine
Disease / condition
Treatment of visceral leishmaniasis
Date of first decision
12/06/2002
Outcome
Positive
EU designation number
EU/3/02/104

Sponsor's contact details

Zentaris Aktiengesellschaft
Weismüllerstrasse 45
D- 60314 Frankfurt am Main
Germany
Telephone: +49 42602 3435
Telefax: +49 42602 3444
E-mail: matthias.seeber@zentaris.de

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating